Next Article in Journal
Photoreactivity of Hair Melanin from Different Skin Phototypes—Contribution of Melanin Subunits to the Pigments Photoreactive Properties
Next Article in Special Issue
A Heterotypic Tridimensional Model to Study the Interaction of Macrophages and Glioblastoma In Vitro
Previous Article in Journal
A Role for TGFβ Signaling in Preclinical Osteolytic Estrogen Receptor-Positive Breast Cancer Bone Metastases Progression
Previous Article in Special Issue
A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in Glioblastoma
Review

An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5

1
Department of Genetic Toxicology and Cancer Biology, National Institute of Biology, 1000 Ljubljana, Slovenia
2
Faculty of Chemistry and Chemical Technology, University of Ljubljana, 1000 Ljubljana, Slovenia
3
Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, 3805 Old Easton Road, Doylestown, PA 18902, USA
4
School of Medicine, Xavier University, Santa Helenastraat #23, Oranjestad, Aruba
5
Division of Perinatal Research, Kolling Institute, Northern Sydney Local Health District, St Leonards, NSW 2065, Australia
6
Sydney Medical School Northern, University of Sydney, Sydney, NSW 2006, Australia
7
Lankenau Institute for Medical Research Philadelphia, 100 East Lancaster Ave., Wynnewood, PA 19069, USA
8
Medical School, Faculty of Health and Medical Sciences, The University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia
9
The Wistar Cancer Center, Philadelphia, PA 19107, USA
*
Authors to whom correspondence should be addressed.
Academic Editor: Guillermo Gomez
Int. J. Mol. Sci. 2021, 22(9), 4464; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22094464
Received: 4 April 2021 / Revised: 20 April 2021 / Accepted: 21 April 2021 / Published: 24 April 2021
The mechanisms governing therapeutic resistance of the most aggressive and lethal primary brain tumor in adults, glioblastoma, have increasingly focused on tumor stem cells. These cells, protected by the periarteriolar hypoxic GSC niche, contribute to the poor efficacy of standard of care treatment of glioblastoma. Integrated proteogenomic and metabolomic analyses of glioblastoma tissues and single cells have revealed insights into the complex heterogeneity of glioblastoma and stromal cells, comprising its tumor microenvironment (TME). An additional factor, which isdriving poor therapy response is the distinct genetic drivers in each patient’s tumor, providing the rationale for a more individualized or personalized approach to treatment. We recently reported that the G protein-coupled receptor CCR5, which contributes to stem cell expansion in other cancers, is overexpressed in glioblastoma cells. Overexpression of the CCR5 ligand CCL5 (RANTES) in glioblastoma completes a potential autocrine activation loop to promote tumor proliferation and invasion. CCL5 was not expressed in glioblastoma stem cells, suggesting a need for paracrine activation of CCR5 signaling by the stromal cells. TME-associated immune cells, such as resident microglia, infiltrating macrophages, T cells, and mesenchymal stem cells, possibly release CCR5 ligands, providing heterologous signaling between stromal and glioblastoma stem cells. Herein, we review current therapies for glioblastoma, the role of CCR5 in other cancers, and the potential role for CCR5 inhibitors in the treatment of glioblastoma. View Full-Text
Keywords: CCL5; CCR5; cytokines; glioblastoma; glioblastoma stem cells; intertumoral heterogeneity; perivascular niche; glioblastoma therapy CCL5; CCR5; cytokines; glioblastoma; glioblastoma stem cells; intertumoral heterogeneity; perivascular niche; glioblastoma therapy
Show Figures

Graphical abstract

MDPI and ACS Style

Lah Turnšek, T.; Jiao, X.; Novak, M.; Jammula, S.; Cicero, G.; Ashton, A.W.; Joyce, D.; Pestell, R.G. An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5. Int. J. Mol. Sci. 2021, 22, 4464. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22094464

AMA Style

Lah Turnšek T, Jiao X, Novak M, Jammula S, Cicero G, Ashton AW, Joyce D, Pestell RG. An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5. International Journal of Molecular Sciences. 2021; 22(9):4464. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22094464

Chicago/Turabian Style

Lah Turnšek, Tamara, Xuanmao Jiao, Metka Novak, Sriharsha Jammula, Gina Cicero, Anthony W. Ashton, David Joyce, and Richard G. Pestell 2021. "An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5" International Journal of Molecular Sciences 22, no. 9: 4464. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22094464

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop